Correlation Between Viracta Therapeutics and Actinium Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Viracta Therapeutics and Actinium Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viracta Therapeutics and Actinium Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viracta Therapeutics and Actinium Pharmaceuticals, you can compare the effects of market volatilities on Viracta Therapeutics and Actinium Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viracta Therapeutics with a short position of Actinium Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viracta Therapeutics and Actinium Pharmaceuticals.

Diversification Opportunities for Viracta Therapeutics and Actinium Pharmaceuticals

-0.75

Correlation Coefficient

Viracta Therapeutics  Actinium Pharmaceuticals

Pay attention - limited upside

The 3 months correlation between Viracta and Actinium is -0.75. Overlapping area represents the amount of risk that can be diversified away by holding Viracta Therapeutics and Actinium Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Actinium Pharmaceuticals and Viracta Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viracta Therapeutics are associated (or correlated) with Actinium Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Actinium Pharmaceuticals has no effect on the direction of Viracta Therapeutics i.e., Viracta Therapeutics and Actinium Pharmaceuticals go up and down completely randomly.

Pair Corralation between Viracta Therapeutics and Actinium Pharmaceuticals

Given the investment horizon of 90 days Viracta Therapeutics is expected to under-perform the Actinium Pharmaceuticals. In addition to that, Viracta Therapeutics is 2.79 times more volatile than Actinium Pharmaceuticals. It trades about -0.28 of its total potential returns per unit of risk. Actinium Pharmaceuticals is currently generating about 0.15 per unit of volatility. If you would invest  117.00  in Actinium Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of  64.00  from holding Actinium Pharmaceuticals or generate 54.7% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	42.62%
Values	Daily Returns

Viracta Therapeutics  vs.  Actinium Pharmaceuticals

Viracta Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Viracta Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Actinium Pharmaceuticals

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in Actinium Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. In spite of very uncertain basic indicators, Actinium Pharmaceuticals displayed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Viracta Therapeutics and Actinium Pharmaceuticals

The main advantage of trading using opposite Viracta Therapeutics and Actinium Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viracta Therapeutics position performs unexpectedly, Actinium Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Actinium Pharmaceuticals will offset losses from the drop in Actinium Pharmaceuticals' long position.

The idea behind Viracta Therapeutics and Actinium Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.